![]() |
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
NEUROPHARMACOLOGY
Department of Pharmacology and the Center for Drug Discovery, University of California, Irvine, California (J.L., J.F. D.P.); Department of Experimental Pharmacology, University of Naples, Naples, Italy (R.R., G.L., G.M.R., R.M., A.C.); and Department of Psychology, University of Georgia, Athens, Georgia (J.F., A.H.)
Severe pain remains a major area of unmet medical need. Here we report that agonists of the nuclear receptor PPAR-
(peroxisome proliferator-activated receptor-
) suppress pain behaviors induced in mice by chemical tissue injury, nerve damage, or inflammation. The PPAR-
agonists GW7647 [2-(4-(2-(1-cyclohexanebutyl)-3-cyclohexylureido)ethyl)phenylthio)-2-methylpropionic acid], Wy-14643 [4-chloro-6-(2,3-xylidino)-2-pyrimidinylthioacetic acid], and palmitoylethanolamide (PEA) reduced nocifensive behaviors elicited in mice by intraplantar (i.pl.) injection of formalin or i.p. injection of magnesium sulfate. These effects were absent in PPAR-
-null mice yet occurred within minutes of agonist administration in wild-type mice, suggesting that they were mediated through a transcription-independent mechanism. Consistent with this hypothesis, blockade of calcium-operated IKca (KCa3.1) and BKca (KCa1.1) potassium channels prevented the effects of GW7647 and PEA in the formalin test. Three observations suggest that PPAR-
agonists may inhibit nocifensive responses by acting on peripheral PPAR-
. (i) PEA reduced formalin-induced pain at i.pl. doses that produced no increase in systemic PEA levels; (ii) PPAR-
was expressed in dorsal root ganglia neurons of wild-type but not PPAR-
-null mice; and (ii) GW7647 and PEA prevented formalin-induced firing of spinal cord nociceptive neurons in rats. In addition to modulating nociception, GW7647 and PEA reduced hyperalgesic responses in the chronic constriction injury model of neuropathic pain; these effects were also contingent on PPAR-
expression and were observed following either acute or subchronic PPAR-
agonist administration. Finally, acute administration of GW7647 and PEA reduced hyperalgesic responses in the complete Freund's adjuvant and carrageenan models of inflammatory pain. Our results suggest that PPAR-
agonists may represent a novel class of analgesics.
Address correspondence to: Dr. Daniele Piomelli, Department of Pharmacology, University of California, Irvine, 360 MSRII, Irvine, CA 92697-4625. E-mail: piomelli{at}uci.edu
This article has been cited by other articles:
![]() |
C. Mazzola, J. Medalie, M. Scherma, L. V. Panlilio, M. Solinas, G. Tanda, F. Drago, J. L. Cadet, S. R. Goldberg, and S. Yasar Fatty acid amide hydrolase (FAAH) inhibition enhances memory acquisition through activation of PPAR-{alpha} nuclear receptors Learn. Mem., April 29, 2009; 16(5): 332 - 337. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. J. Lever, M. Robinson, M. Cibelli, C. Paule, P. Santha, L. Yee, S. P. Hunt, B. F. Cravatt, M. R. Elphick, I. Nagy, et al. Localization of the Endocannabinoid-Degrading Enzyme Fatty Acid Amide Hydrolase in Rat Dorsal Root Ganglion Cells and Its Regulation after Peripheral Nerve Injury J. Neurosci., March 25, 2009; 29(12): 3766 - 3780. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. J. Karbarz, L. Luo, L. Chang, C.-S. Tham, J. A. Palmer, S. J. Wilson, M. L. Wennerholm, S. M. Brown, B. P. Scott, R. L. Apodaca, et al. Biochemical and Biological Properties of 4-(3-phenyl-[1,2,4] thiadiazol-5-yl)-piperazine-1-carboxylic acid phenylamide, a Mechanism-Based Inhibitor of Fatty Acid Amide Hydrolase Anesth. Analg., January 1, 2009; 108(1): 316 - 329. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Melis, G. Pillolla, A. Luchicchi, A. L. Muntoni, S. Yasar, S. R. Goldberg, and M. Pistis Endogenous Fatty Acid Ethanolamides Suppress Nicotine-Induced Activation of Mesolimbic Dopamine Neurons through Nuclear Receptors J. Neurosci., December 17, 2008; 28(51): 13985 - 13994. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Fu, J. Kim, F. Oveisi, G. Astarita, and D. Piomelli Targeted enhancement of oleoylethanolamide production in proximal small intestine induces across-meal satiety in rats Am J Physiol Regulatory Integrative Comp Physiol, July 1, 2008; 295(1): R45 - R50. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. H. Napimoga, G. R. Souza, T. M. Cunha, L. F. Ferrari, J. T. Clemente-Napimoga, C. A. Parada, W. A. Verri Jr., F. Q. Cunha, and S. H. Ferreira 15d-Prostaglandin J2 Inhibits Inflammatory Hypernociception: Involvement of Peripheral Opioid Receptor J. Pharmacol. Exp. Ther., January 1, 2008; 324(1): 313 - 321. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. H. Napimoga, S. M. Vieira, D. Dal-Secco, A. Freitas, F. O. Souto, F. L. Mestriner, J. C. Alves-Filho, R. Grespan, T. Kawai, S. H. Ferreira, et al. Peroxisome Proliferator-Activated Receptor-{gamma} Ligand, 15-Deoxy-{Delta}12,14-Prostaglandin J2, Reduces Neutrophil Migration via a Nitric Oxide Pathway J. Immunol., January 1, 2008; 180(1): 609 - 617. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. D'Agostino, G. La Rana, R. Russo, O. Sasso, A. Iacono, E. Esposito, G. M. Raso, S. Cuzzocrea, J. Lo Verme, D. Piomelli, et al. Acute Intracerebroventricular Administration of Palmitoylethanolamide, an Endogenous Peroxisome Proliferator-Activated Receptor-{alpha} Agonist, Modulates Carrageenan-Induced Paw Edema in Mice J. Pharmacol. Exp. Ther., September 1, 2007; 322(3): 1137 - 1143. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. D. Teaster, C. M. Motes, Y. Tang, W. C. Wiant, M. Q. Cotter, Y.-S. Wang, A. Kilaru, B. J. Venables, K. H. Hasenstein, G. Gonzalez, et al. N-Acylethanolamine Metabolism Interacts with Abscisic Acid Signaling in Arabidopsis thaliana Seedlings PLANT CELL, August 1, 2007; 19(8): 2454 - 2469. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Russo, J. LoVerme, G. La Rana, T. R. Compton, J. Parrott, A. Duranti, A. Tontini, M. Mor, G. Tarzia, A. Calignano, et al. The Fatty Acid Amide Hydrolase Inhibitor URB597 (Cyclohexylcarbamic Acid 3'-Carbamoylbiphenyl-3-yl Ester) Reduces Neuropathic Pain after Oral Administration in Mice J. Pharmacol. Exp. Ther., July 1, 2007; 322(1): 236 - 242. [Abstract] [Full Text] [PDF] |
||||